SNAP Update and ResourcesActualización y recursos de SNAP
On November 1, 2025, the requirements to receive and apply to the Supplemental Nutrition Assistance Program (SNAP) benefits have changed. To see the new policies to request SNAP benefits, click here and/or call 211 for SNAP assistance. Learn more
El 1 de noviembre de 2025, cambiaron los requisitos para recibir y aplicar para los beneficios del Programa de Asistencia Nutricional Suplementaria (SNAP, por sus siglas en inglés). Para consultar las nuevas políticas para aplicar para los beneficios de SNAP, haz clic aquí o llama al 211 para obtener ayuda de SNAP. Aprende Más
Transportation UpdateActualización de transporte
SafeRide Health (SRH) is the new provider for all NEMT rides to doctor appointments and pharmacy visits.
Depending on your needs, rides may include wheelchair-lift-equipped vehicles, stretcher vans, minivans, or ambulatory vans. Please let SRH know what type of ride you need when scheduling.
SafeRide Health (SRH) es el nuevo proveedor de todos los servicios de transporte médico que no son de emergencia (NEMT, por sus siglas en inglés) hacia consultas médicas y farmacias.
Según tus necesidades, los servicios de transporte pueden incluir vehículos con elevador para sillas de ruedas, camionetas con camilla, minivans o camionetas ambulatorias. Por favor, informa a SRH qué tipo de transporte necesitas al programar tu traslado.
Texas Medicaid PDL Changes for Ustekinumab (Stelara) Products
Date: September 17, 2025
Attention: All Providers
Effective date: July 28, 2025
Call to action: Texas Children’s Health Plan (TCHP) would like inform providers that effective July 28, 2025 the Texas Health and Human Services Commission (HHSC) has updated the Texas Medicaid Preferred Drug List (PDL) for ustekinumab (Stelara) Products.
Two FDA approved interchangeable biosimilars are now available as preferred medications on the Texas Medicaid PDL: Pyzchiva (ustekinumab-TTWE) and Selarsdi (ustekinumab-aekn). Stelara is non-preferred and will require PDL prior authorization. These two interchangeable biosimilars are available at a considerable cost savings compared to Stelara, reflecting HHSC’s ongoing review of clinical evidence supporting biosimilar equivalence and cost-effectiveness.
Texas Medicaid PDL Preferred
Texas Medicaid PDL Non-Preferred
PYZCHIVA (ustekinumab-TTWE)
SELARSDI (ustekinumab-AEKN)
STELARA (ustekinumab)
As healthcare expenditures rise, biosimilar drugs represent a clear opportunity to reduce healthcare costs while maintaining patient access to treatment options for patients. To support this goal, we encourage providers to consider transitioning patients currently prescribed Stelara to Pyzchiva (ustekinumab-TTWE) or Selarsdi (ustekinumab-aekn) when clinically appropriate or in the best interest of your patient. This can be accomplished by either writing a new prescription for Pychiva or Selarsdi with a DAW-1 (Dispense-As-Written) notation. An interchangeable biosimilar is a biosimilar that meets additional requirements for clinical equivalency, and are as safe and effective as the original biologic they were compared to.
Next steps: Providers should share this communication with their staff.
